Precision Oncology: The Road Ahead

By Daniela Senft, Mark D. M. Leiserson, Eytan Ruppin, Z. Ronai. 2017

152 citations recorded by the source corpus.

Current efforts in precision oncology largely focus on the benefit of genomics-guided therapy. Yet, advances in sequencing techniques provide an unprecedented view of the complex genetic and non-genetic heterogeneity within individual tumors. Herein, we outline the benefits of integrating genomic and transcriptomic analyses for advanced precision oncology. We summarize relevant computational approaches to detect novel drivers and genetic vulnerabilities, suitable for therapeutic exploration. Clinically relevant platforms to functionally test predicted drugs/drug combinations for individual patients are reviewed. Finally, we highlight the technological advances in single-cell analysis of tumor specimens. These may ultimately lead to the development of next generation cancer drugs, capable of tackling the hurdles imposed by genetic and phenotypic heterogeneity on current anticancer therapies.

Subfields: Cancer Research, Molecular Biology, Oncology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. E. Malone
2. M. Oliva
3. P. Sabatini
4. L. Siu
5. T. Stockley

Citations in the corpus

• Molecular profiling for precision cancer therapies (2020, background): “The detection of gene expression networks and of the activity of oncogenic pathways through transcriptomic analyses can add a more “functional” tumor profiling that can ultimately increase treatment opportunities [116].”